|
|
Found results for
 patents
1.
|
IN VITRO PRODUCTION OF HETEROLOGOUS POLYNUCLEOTIDES AND POLYPEPTIDES IN TRYPANOSOMES
| Application Number |
US2026012264 |
| Publication Number |
2026/161640 |
| Status |
In Force |
| Filing Date |
2026-01-23 |
| Publication Date |
2026-07-30 |
| Owner |
SIMMBION, LLC (USA)
|
| Inventor |
- Getnet, Derese
- Darrah, Erika
- Collins, Samuel
|
Abstract
in vitroTrypanosomesTrypanosomesTrypanosomesin vitroin vitro under controlled, large-scale manufacturing conditions, which can then be recovered and administered to a host.
IPC Classes ?
- A61K 39/005 - Trypanosoma antigens
- C12N 1/10 - ProtozoaCulture media therefor
- C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
|
2.
|
SYSTEMS, DEVICES, AND METHODS FOR IN VIVO GENERATION OF SUBSTANCES USING NONPATHOGENIC MICROORGANISMS
| Document Number |
03299253 |
| Status |
Pending |
| Filing Date |
2024-07-28 |
| Open to Public Date |
2025-01-30 |
| Owner |
SIMMBION, LLC (USA)
|
| Inventor |
- Getnet, Derese
- Darrah, Erika
- Collins, Samuel
|
IPC Classes ?
- A61K 38/22 - Hormones
- A61K 38/28 - Insulins
- A61K 39/005 - Trypanosoma antigens
- C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
- C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
- C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
|
3.
|
IN VIVO GENERATION OF SUBSTANCES USING NONPATHOGENIC MICROORGANISMS
| Application Number |
US2024039958 |
| Publication Number |
2025/024837 |
| Status |
In Force |
| Filing Date |
2024-07-28 |
| Publication Date |
2025-01-30 |
| Owner |
SIMMBION, LLC (USA)
|
| Inventor |
- Getnet, Derese
- Darrah, Erika
- Collins, Samuel
|
Abstract
in vivoTrypanosoma rangeliTrypanosoma rangeli, a nonpathogenic microorganism may be purposefully engineered, altered, and designed to be a blood symbiont in humans and animals after genetic modification to express foreign nucleic acid sequences that encode proteins, polynucleotides, and/or pathways to treat disease or enhance specific aspects of host physiology to include metabolic dominance to correct or augment homeostatic imbalances when suitable. The foreign nucleic acid sequences may be used to generate enzymes, scavenger molecules, peptides and hormones, antibodies, nanobodies, signaling ligands, and other therapeutic or novel synthetic agents.
IPC Classes ?
- A61K 39/005 - Trypanosoma antigens
- A61K 39/00 - Medicinal preparations containing antigens or antibodies
- C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
- C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
- C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
- A61K 38/28 - Insulins
- A61K 38/22 - Hormones
|
|
